Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate (NYSE:CLVT) has released its fourth annual sustainability report, highlighting significant achievements in 2023. The company was recognized by Newsweek as one of 'America's Greatest Workplaces for Diversity' and 'America's Greenest Companies' for 2024. Notable milestones include 49% of revenue aligned with UN SDGs and partnerships with 53% of companies in the Dow Jones Sustainability World Index.
The company joined several UN initiatives and achieved an 80 score in the Human Rights Campaign's Corporate Equality Index. Employees contributed 23,242 volunteer hours through a 40-hour paid volunteer program. Clarivate's impact extends to supporting 95M+ patients in healthcare, 130M+ students, and 26K+ libraries, while working with 46 of the top 50 R&D companies globally.
Clarivate (NYSE:CLVT) has launched ProQuest One Sustainability, a comprehensive research solution designed to support sustainability curricula across research, teaching, and learning. The platform features over 1,500 scholarly journals, 40,000+ full-text case studies, and content from 37,000+ dissertations and theses.
The solution offers a transdisciplinary approach structured around sustainability's environmental, social, and economic pillars, aligned with the United Nations Sustainable Development Goals. It includes the AI-powered ProQuest Research Assistant to help users craft targeted searches and analyze documents effectively.
The platform covers important topics like climate change, renewable energy, environmental justice, and sustainable business practices, supporting Clarivate's commitment to sustainability and quality education.
Clarivate (NYSE: CLVT) reported Q3 2024 financial results showing revenue decline to $622.2 million, down 3.9%, with organic revenues decreasing 2.6%. The company posted a net loss of $65.6 million ($0.09 per diluted share). Adjusted EBITDA fell 6.0% to $264.4 million, with margins declining 100 basis points to 42.5%. Free cash flow improved to $126.3 million. For the nine months ended September 30, revenues declined 2.6% to $1,893.7 million, with a net loss of $444.9 million. The CEO acknowledged unsatisfactory results, citing overdependence on fluctuating transactional revenue and announced a Value Creation Plan to improve performance.
Silverchair, a Thompson Street Capital Partners portfolio company, has announced an agreement to acquire ScholarOne from Clarivate Plc (NYSE:CLVT). Silverchair provides software and services to STM content publishers, serving over 400 publishers through its content management system. ScholarOne, specializing in manuscript submission and peer review management, serves more than 600 publishers and processes over three million manuscripts annually. The acquisition aims to create a comprehensive solution for scholarly publishing and is expected to close in Q4 2024.
Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will release its third quarter 2024 financial results on Wednesday, November 6, 2024, before the market opens. The company will also host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.
Investors and interested parties can access the press release, earnings supplement, and accompanying financial information on the Clarivate investor website at https://ir.clarivate.com. The webcast will be open to all interested parties and may include forward-looking information.
Clarivate Plc (NYSE:CLVT) has announced the success of its annual Citation Laureates™ program, accurately predicting eight Nobel Prize 2024 recipients. The program, powered by the Web of Science Core Collection™ citation index, combines citation analysis with expert insights to identify potential Nobel laureates. Since 2002, 83 out of 441 Citation Laureates have received a Nobel Prize, with successful forecasts every year since 2007.
Notable predictions include David Baker, Demis Hassabis, and John M. Jumper for the Nobel in Chemistry, Victor Ambros and Gary Ruvkun for Physiology or Medicine, and Daron Acemoglu, Simon Johnson, and James A. Robinson for Economic Sciences. The success of the program highlights the value of Clarivate's data-driven approach in identifying researchers with exceptional citation records and potential Nobel honors.
Clarivate and Abiquifi have announced the agenda for the 2nd annual Summit LATAM, scheduled for October 7, 2024, in Milan. The event, preceding CPHI Milan, will focus on AI, data, strategic partnerships, and innovation opportunities in the Latin American pharmaceutical market, valued at $98 billion with projected growth of 10.1%.
Key sessions will cover topics such as driving growth with data and AI, competitive partnerships, regulatory guidelines, and local API production. The summit aims to address challenges and uncover opportunities in the region's evolving pharmaceutical landscape. Industry leaders from Clarivate, Abiquifi, Knight Therapeutics, EMS, Gene Pharm, Libbs Farmacêutica, ANVISA, Nortec, Emcure Mexico, and Globe Química will share insights and perspectives.
Clarivate Plc (NYSE:CLVT) has unveiled a comprehensive framework for evaluating the societal impact of research. The approach, detailed in a new report by the Institute for Scientific Information (ISI)™, addresses the growing demand for demonstrating the benefits of R&D investments across various sectors of society.
The framework categorizes societal needs into eight facets: Political & Policy, Legal & Governance, Economic, Human Capital, Medical, Social & Cultural, Technological and Environmental. It aims to balance qualitative and quantitative approaches, extending beyond traditional quantitative indicators.
To address the challenge of long timeframes between research discovery and societal application, the framework incorporates both lagging and leading indicators. This new approach will be integrated into the upcoming Web of Science Research Intelligence™ platform.
Clarivate Plc (NYSE: CLVT) has released a new report titled 'Excellence in IP Operations' based on a global survey of 184 IP professionals. The report highlights key challenges and trends shaping intellectual property (IP) operations, focusing on strategy alignment, resource allocation, technology enablement, and AI adoption.
Key findings include:
- 65% of corporate respondents with clear KPIs reported alignment between IP and business strategies
- Well-managed operational processes correlate with greater strategic alignment and efficient staff use
- 83% of respondents spending over half their time on unrelated tasks were not using AI in their IP department
- 64% of respondents dissatisfied with their technology setup spent more time on tasks outside their primary role
The report emphasizes the importance of aligning KPIs with business goals, effective process management, closing the AI adoption gap, and leveraging technology for efficiency in IP operations.
Clarivate Plc (NYSE: CLVT) has announced a strategic partnership with Relatable Healthcare to enhance medtech sales contracting processes. This collaboration integrates Clarivate's comprehensive competitive intelligence into Relatable's Product Relationship Management (PRM) platform, providing medtech companies with a single source of truth for product information and competitive data.
The partnership aims to empower clients to make informed pricing decisions, streamline sales contracting, and improve contract compliance. It addresses the challenges faced by medical device and supply companies in communicating product value and offering consultative insights in a cost-constrained healthcare environment.
By combining Clarivate's deep product-level market knowledge with Relatable Healthcare's enterprise software, the partnership equips medtech companies with tools to win new business and drive contract compliance more efficiently, particularly when serving Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), and various healthcare providers.